Inactive Instrument

Sigilon Therapeutics, Inc.

Equities

SGTX

US82657L2060

Biotechnology & Medical Research

Sigilon Therapeutics, Inc. Terminates the Employment of May Orfali as Chief Medical Officer

February 13, 2023 at 04:31 pm EST

On February 10, 2023, Sigilon Therapeutics, Inc. terminated the employment of May Orfali, M.D., the Company's Chief Medical Officer, effective February 10, 2023. In addition, the Company expects that Dr. Orfali will provide consulting services to the Company for a period of at least three months at a mutually agreed upon hourly rate.

Latest news about Sigilon Therapeutics, Inc.

Eli Lilly Completes Purchase of Sigilon Therapeutics in Cash Deal	23-08-14	MT
Eli Lilly Completes Acquisition of Sigilon Therapeutics	23-08-14	MT
Sigilon Therapeutics, Inc. Announces Board Changes	23-08-11	CI
Sigilon Therapeutics, Inc.(NasdaqGM:SGTX) dropped from NASDAQ Composite Index	23-08-11	CI
Sigilon Therapeutics, Inc.(NasdaqGS:SGTX) dropped from S&P TMI Index	23-08-11	CI
Eli Lilly and Company completed the acquisition of remaining 91.56% stake in Sigilon Therapeutics, Inc. from Flagship Ventures Fund V, L.P. and Flagship Pioneering Special Opportunities Fund II, L.P., managed by Flagship Pioneering and others.	23-08-10	CI
Sigilon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Canaccord Genuity Adjusts Price Target on Sigilon Therapeutics to $30 From $6, Maintains Buy Rating	23-07-05	MT
North American Morning Briefing : China Data -2-	23-07-05	DJ
North American Morning Briefing : Tesla Bounce -2-	23-07-03	DJ
Morgan Stanley Adjusts Price Target on Sigilon Therapeutics to $21 From $7, Maintains Equalweight Rating	23-06-30	MT
BTIG Downgrades Sigilon Therapeutics to Neutral From Buy	23-06-30	MT
Sector Update: Health Care Stocks Advancing Late Thursday	23-06-29	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	23-06-29	MT
Top Midday Gainers	23-06-29	MT
Top Stories at Midday: US Q1 GDP Revised Higher; Jobless Claims Post Surprise Drop; Powell Reiterates Comments; BioXcel Therapeutics Tumbles	23-06-29	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	23-06-29	MT
Sector Update: Health Care	23-06-29	MT
Traders Cheer After Bank Stress Test Results, Lifting US Equity Futures	23-06-29	MT
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments	23-06-29	RE
Top Premarket Gainers	23-06-29	MT
Eli Lilly to Acquire Sigilon Therapeutics in Deal Potentially Worth More Than $300 Million; Sigilon Shares Surge	23-06-29	MT
Eli Lilly to Buy Chronic Disease-focused Sigilon Therapeutics	23-06-29	MT
Eli Lilly to Acquire Sigilon Therapeutics	23-06-29	DJ
Eli Lilly Agrees to Acquire Sigilon Therapeutics for up to $309.6 Million	23-06-29	MT

Chart Sigilon Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sigilon Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company's Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company's lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). It is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. It also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.01%	50.85B
IQVIA HOLDINGS INC.	+1.06%	42.82B
LONZA GROUP AG	+48.94%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.05%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.57%	19.13B
BIO-TECHNE CORPORATION	+8.35%	13.05B
MEDPACE HOLDINGS, INC.	+27.33%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.45%	12.08B

Other Biotechnology & Medical Research